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BACKGROUND
Polymer-free drug-coated stents provide superior clinical outcomes to bare-metal 
stents in patients at high bleeding risk who undergo percutaneous coronary inter-
vention (PCI) and are treated with 1 month of dual antiplatelet therapy. Data on 
the use of polymer-based drug-eluting stents, as compared with polymer-free 
drug-coated stents, in such patients are limited.
METHODS
In an international, randomized, single-blind trial, we compared polymer-based 
zotarolimus-eluting stents with polymer-free umirolimus–coated stents in patients 
at high bleeding risk. After PCI, patients were treated with 1 month of dual anti-
platelet therapy, followed by single antiplatelet therapy. The primary outcome was 
a safety composite of death from cardiac causes, myocardial infarction, or stent 
thrombosis at 1 year. The principal secondary outcome was target-lesion failure, 
an effectiveness composite of death from cardiac causes, target-vessel myocardial 
infarction, or clinically indicated target-lesion revascularization. Both outcomes 
were powered for noninferiority.
RESULTS
A total of 1996 patients at high bleeding risk were randomly assigned in a 1:1 
ratio to receive zotarolimus-eluting stents (1003 patients) or polymer-free drug-
coated stents (993 patients). At 1 year, the primary outcome was observed in 169 
of 988 patients (17.1%) in the zotarolimus-eluting stent group and in 164 of 969 
(16.9%) in the polymer-free drug-coated stent group (risk difference, 0.2 percent-
age points; upper boundary of the one-sided 97.5% confidence interval [CI], 3.5; 
noninferiority margin, 4.1; P = 0.01 for noninferiority). The principal secondary 
outcome was observed in 174 patients (17.6%) in the zotarolimus-eluting stent 
group and in 169 (17.4%) in the polymer-free drug-coated stent group (risk differ-
ence, 0.2 percentage points; upper boundary of the one-sided 97.5% CI, 3.5; non-
inferiority margin, 4.4; P = 0.007 for noninferiority).
CONCLUSIONS
Among patients at high bleeding risk who received 1 month of dual antiplatelet 
therapy after PCI, use of polymer-based zotarolimus-eluting stents was noninfe-
rior to use of polymer-free drug-coated stents with regard to safety and effective-
ness composite outcomes. (Funded by Medtronic; ONYX ONE ClinicalTrials.gov 
number, NCT03344653.)
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Contemporary drug-eluting stents are the standard of care for patients un-dergoing percutaneous coronary interven-
tion (PCI).1,2 Nearly one third of patients treated 
with PCI are considered to be at high bleeding 
risk and are frequently excluded from stent tri-
als.3,4 Short durations of dual antiplatelet therapy 
were used during the bare-metal stent era and 
have been evaluated5 in a few trials comparing 
bare-metal stents with drug-eluting stents6,7 in 
patients at high bleeding risk.8
In the LEADERS FREE trial, a polymer-free 
umirolimus-coated stent was shown to be supe-
rior in safety and effectiveness to a bare-metal 
stent in patients at high bleeding risk who received 
1 month of dual antiplatelet therapy.9 However, 
data on a direct comparison between polymer-free 
drug-coated stents and drug-eluting stents are 
limited. Polymer-based zotarolimus-eluting stents 
have been shown to be safe and effective in a large, 
“all-comer” population of patients (i.e., a trial 
population that had minimal exclusion crite-
ria).10,11 A post hoc analysis of trials of the zotaro-
limus-eluting stent suggested that 1 month of 
dual antiplatelet therapy may be safe after PCI.12 
We designed a randomized trial to compare the 
safety and effectiveness of the polymer-based 
zotarolimus-eluting stent with the polymer-free 
umirolimus-coated stent in patients at high bleed-
ing risk receiving 1 month of dual antiplatelet 
therapy after PCI.13
Me thods
Trial Design and Oversight
ONYX ONE was a randomized, single-blind trial, 
the design of which has been described previ-
ously.13 Patients were enrolled at 84 centers in 
Asia, Oceania, and Europe (see the Supplementary 
Appendix, available with the full text of this ar-
ticle at NEJM.org). Local ethics review boards ap-
proved the protocol (available at NEJM.org), all 
the patients provided written informed consent, 
and the trial adhered to the principles of the 
Declaration of Helsinki.
The trial was funded by Medtronic, and the 
protocol was developed jointly by the executive 
committee and the sponsor (Table S1 in the Sup-
plementary Appendix). Investigators at each site 
gathered the data, which were stored and ana-
lyzed by the sponsor. All the statistical analyses 
were performed by the sponsor and validated in-
dependently by the Baim Institute for Clinical Re-
search. The sponsor was responsible for site selec-
tion, data monitoring, and overall clinical-trial 
management. An external, independent data and 
safety monitoring board and clinical-events com-
mittee assessed safety and performed event adju-
dication. Source document monitoring was per-
formed in 100% of patient records. An independent 
angiographic core laboratory evaluated all base-
line and event angiograms. The Cardiovascular 
Research Foundation oversaw the data and safety 
monitoring board, the clinical-events committee, 
and the angiographic core laboratory.
The first draft of the manuscript was written 
by the first author. All the authors had full access 
to the data, revised the manuscript, supported the 
decision to submit the manuscript for publica-
tion, and vouch for the accuracy and complete-
ness of the data and for the fidelity of the trial 
to the protocol.
Patient Population
Eligible patients had coronary artery disease and 
a clinical indication for PCI. In addition, patients 
were classified as being at high bleeding risk or 
were otherwise a candidate for short-term prophy-
laxis for stent thrombosis (1 month of either dual 
antiplatelet therapy or single antiplatelet therapy 
plus an anticoagulant drug). Complete inclusion 
and exclusion criteria, including the criteria de-
fining high bleeding risk, are listed in Table S2.
Trial Procedures
Patients were randomly assigned in a 1:1 ratio to 
receive either the durable-polymer, slow-release 
zotarolimus-eluting Resolute Onyx stent (Medtron-
ic) or the polymer-free umirolimus-coated Bio-
Freedom stent (BioSensors Interventional Tech-
nologies) after it was confirmed on coronary 
angiography that one or more target lesions were 
eligible for implantation with either type of stent 
(see the Supplementary Appendix). Randomiza-
tion was performed with the use of an interactive 
voice- or Web-response system and was strati-
fied according to trial site, diabetes status, and 
myocardial infarction at time of presentation, 
with a block size of four. Although the interven-
tional cardiologists were aware of the trial-group 
assignments, the patients, referring physicians, 
and personnel conducting patient follow-up, in-
cluding the members of the clinical-events com-
mittee, were unaware of the group assignments.
Operators were instructed to implant the as-
signed stent type during the index procedure 
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and any subsequent staged procedures. If the 
assigned trial stent could not be placed, the 
comparator device was to be used. A clinically 
indicated planned staged procedure was allowed 
within 1 month after the index procedure.
Before the procedure, a loading dose of 250 
to 500 mg of aspirin was recommended in pa-
tients who had not been taking aspirin; oral 
P2Y12 inhibitor pretreatment and loading doses 
were administered according to the local stan-
dard of care. During the index procedure, hepa-
rin or bivalirudin was administered according to 
standard practice, and the use of glycoprotein 
IIb/IIIa blockers was according to the discretion 
of the operator.
After the procedure, patients were given a 
prescription for 1 month of dual antiplatelet 
therapy that included a daily dose (75 to 100 mg) 
of aspirin and a P2Y12 inhibitor. Patients who 
were treated with oral anticoagulants could re-
ceive single or dual antiplatelet therapy during 
this period. After 1 month, patients were given 
a prescription for single antiplatelet therapy (ei-
ther aspirin or a P2Y12 inhibitor, at the discretion 
of the physician). Additional information regard-
ing antithrombotic therapy is provided in the 
Supplementary Appendix. After the index proce-
dure, patients were followed up at 1 month (in an 
office visit) and at 2, 6, and 12 months (in an 
office visit or by telephone).
Trial Outcomes
The primary outcome was a safety composite of 
death from cardiac causes, myocardial infarction, 
or definite or probable stent thrombosis at 1 year. 
The principal secondary outcome was an effec-
tiveness outcome of target-lesion failure (a com-
posite of death from cardiac causes, target-vessel 
myocardial infarction, or clinically indicated tar-
get-lesion revascularization) at 1 year. Other sec-
ondary outcomes included the components of the 
primary outcome and the principal secondary 
outcome as well as major adverse cardiac events, 
stroke, and bleeding events. A detailed list of all 
outcomes and their definitions is provided in the 
Supplementary Appendix. Myocardial infarction 
was defined according to the Third Universal 
Definition of Myocardial Infarction.14 Bleeding was 
defined according to Bleeding Academic Research 
Consortium (BARC) criteria (see the End Point 
Definitions section in the Supplementary Appen-
dix). BARC types range from 0 to 5, with higher 
values indicating greater severity of bleeding.
Statistical Analysis
On the basis of the results in the LEADERS FREE 
trial,9 we assumed that 9.4% of the patients in 
each group would have a primary-outcome event. 
A noninferiority margin of 4.1 percentage points 
was chosen, which represented 44% of the ex-
pected percentage of patients with an event. We 
calculated that a sample of 900 patients in each 
group would provide the trial with more than 
90% power to show noninferiority on the basis 
of the Farrington–Manning test at a one-sided 
type I error of 0.05. Under an assumption that 
10% of the patients would be lost to follow-up, 
a total sample of 2000 patients was deemed to 
be sufficient to evaluate the primary outcome. If 
noninferiority regarding the primary outcome was 
established, a conditional test for superiority would 
be performed.
If the zotarolimus-eluting stent was nonin-
ferior to the polymer-free drug-coated stent in 
the analysis of the primary outcome, the prin-
cipal secondary outcome of target-lesion failure 
at 1 year would be tested for noninferiority. In 
the LEADERS FREE trial, 11% of the patients 
were estimated to have target-lesion failure, on 
the basis of the reported components of target-
lesion failure in that trial.9 We selected a nonin-
feriority margin of 4.4 percentage points, which 
represented 40% of the expected percentage of 
patients with an event. If noninferiority regard-
ing the principal secondary outcome was met, a 
conditional test for superiority would be per-
formed.
The results for the primary outcome were 
based on a modified intention-to-treat popula-
tion that excluded patients who withdrew from 
the trial or were lost to follow-up. A sensitivity 
analysis was performed with the use of multiple 
imputation to account for missing data, includ-
ing data for the patients who were lost to follow-
up or withdrew from the trial. Additional analyses 
were performed in the per-protocol and as-treated 
populations; definitions of all the analysis popu-
lations are provided in the Supplementary Ap-
pendix. The 95% confidence intervals presented 
in this article have not been adjusted for multi-
ple comparisons, and therefore inferences drawn 
from these intervals may not be reproducible. In 
a post hoc analysis, the upper boundary of the 
one-sided 97.5% confidence interval, which cor-
responds to a one-sided type I error of 0.025 for 
the primary analysis results, was also calculated.
Categorical data are reported as percentages 
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(counts divided by the number of patients who 
could be evaluated) and were compared with the 
use of Fisher’s exact test. Continuous data are 
reported as means with standard deviations and 
were tested with the use of two-sample Student’s 
t-tests; rates are based on all the patients who 
underwent randomization and had data that 
could be evaluated. For prespecified subgroup 
analyses, the interaction term between treat-
ment groups and subgroups was evaluated with 
the use of logistic regression. Cumulative-inci-
dence curves with Kaplan–Meier estimates were 
generated. Post hoc landmark analyses were 
performed with the use of cutoffs at 30 days, 
which corresponded to the planned date of dis-
continuation of dual antiplatelet therapy. All the 
statistical analyses were performed with the use 




Of 3239 patients enrolled in the trial, 1996 pa-
tients underwent randomization between Novem-
ber 1, 2017, and September 28, 2018; a total of 
1003 patients were assigned to the zotarolimus-
eluting stent and 993 were assigned to the poly-
mer-free drug-coated stent (Fig. S1). A total of 15 
patients (1.5%) assigned to the zotarolimus-
eluting stent group and 24 (2.4%) patients assigned 
to the polymer-free drug-coated stent group were 
lost to follow-up or withdrew consent. The re-
maining patients (988 in the zotarolimus-eluting 
stent group and 969 in the polymer-free drug-
coated stent group) were included in the modi-
fied intention-to-treat analyses at 1 year.
Patients had a mean (±SD) age of 74±10 years, 
frequently had diabetes (770 of 1996 patients 
[38.6%]), and commonly presented with acute 
coronary syndromes (982 of 1902 patients [51.6%]) 
(Table 1). The mean number of high-bleeding-
risk criteria per patient was 1.6; a total of 921 of 
1995 patients (46.2%) met 2 or more criteria. 
The most common high-bleeding-risk qualifying 
features were an age of 75 years or older and 
oral anticoagulation use (Table 2).
Procedural Characteristics
Vascular access was predominantly radial in each 
group, and the number of vessels and lesions 
treated was similar in the two groups (Tables S3 
and S4). Most patients had complex lesions. A 
total of 2 patients assigned to the zotarolimus-
eluting stent crossed over to receive the polymer-
free drug-coated stent, and 40 patients assigned 
to the polymer-free drug-coated stent crossed over 
to receive the zotarolimus-eluting stent (reasons 
are presented in Table S5). The immediate change 
in the dimension of the vessel (often called acute 
gain) was greater and the percentage of the vessel 
diameter with residual stenosis was lower after 
treatment with the zotarolimus-eluting stent than 
with the polymer-free drug-coated stent. Device 
success occurred in 1158 of 1248 lesions (92.8%) 
in patients in the zotarolimus-eluting stent group 
and in 1109 of 1237 lesions (89.7%) in patients in 
the polymer-free drug-coated stent group (differ-
ence, 3.1 percentage points; 95% confidence in-
terval [CI], 0.9 to 5.4).
The timing of the discontinuation of dual an-
tiplatelet therapy was similar in the two groups. 
At 30 days, dual antiplatelet therapy had been 
prescribed in 899 of 980 patients (91.7%) in the 
zotarolimus-eluting stent group and in 901 of 
966 patients (93.3%) in the polymer-free drug-
coated stent group (Fig. S2). At 2 months, 57 of 
969 patients (5.9%) in the zotarolimus-eluting 
stent group and 66 of 954 patients (6.9%) in the 
polymer-free drug-coated stent group were tak-
ing dual antiplatelet therapy; at 1 year, 53 of 899 
patients (5.9%) and 75 of 897 patients (8.4%), 
respectively, were taking dual antiplatelet therapy. 
Single antiplatelet agent therapy at 1 year con-
sisted of aspirin in 451 of 899 patients (50.2%) 
in the zotarolimus-eluting stent group and in 
447 of 897 patients (49.8%) in the polymer-free 
drug-coated stent group and consisted of a P2Y12 
inhibitor in 349 patients (38.8%) and 333 patients 
(37.1%), respectively (Tables S6 through S10).
Primary and Principal Secondary Outcomes
At 1 year, the primary outcome — a composite of 
death from cardiac causes, myocardial infarction, 
or stent thrombosis — had occurred in 169 of 
988 patients (17.1%) in the zotarolimus-eluting 
stent group and in 164 of 969 patients (16.9%) in 
the polymer-free drug-coated stent group (risk dif-
ference, 0.2 percentage points; upper boundary of 
the one-sided 95% CI, 3.0; upper boundary of the 
one-sided 97.5% CI, 3.5; P = 0.01 for noninferiority) 
(Table 3). Cumulative-incidence curves for the pri-
mary outcome and its components are shown in 
Figure 1.
At 1 year, the principal secondary outcome of 
target-lesion failure had occurred in 174 patients 
The New England Journal of Medicine 
Downloaded from nejm.org at UNIVERSITAT DE BARCELONA CRAI on March 9, 2021. For personal use only. No other uses without permission. 
 Copyright © 2020 Massachusetts Medical Society. All rights reserved. 
n engl j med 382;13 nejm.org March 26, 20201212
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
(17.6%) in the zotarolimus-eluting stent group and 
in 169 patients (17.4%) in the polymer-free drug-
coated stent group (risk difference, 0.2 percentage 
points; upper boundary of the one-sided 95% CI, 
3.0; upper boundary of the one-sided 97.5% CI, 3.5; 
P = 0.007 for noninferiority) (Table 3). Cumulative-
incidence curves for the principal secondary out-
come are shown in Figure 2. Subsequent testing 
for superiority did not yield significant between-
group differences for the primary outcome or the 
principal secondary outcome.
Noninferiority was confirmed in the as-treated 
and per-protocol analyses at the one-sided level 
of 0.05 but was not confirmed at the one-sided 
level of 0.025 (Tables S11 and S12). Findings were 
also confirmed in sensitivity analyses that ac-
counted for missing data (Table S13).
Additional Analyses
The incidence of prespecified secondary outcomes, 
including subtypes of myocardial infarction, was 
similar in the two groups (Table 3 and Tables S14 
and S15). Bleeding events that met the criteria for 
BARC grade 2 through 5 occurred in 149 patients 
(15.1%) in the zotarolimus-eluting stent group 
and in 133 patients (13.7%) in the polymer-free 
drug-coated stent group. Stent thrombosis at 1 year 
occurred in 13 patients (1.3%) in the zotaroli-
mus-eluting stent group and in 20 (2.1%) in the 
polymer-free drug-coated stent group (Table 3). 
The risk differences between the two groups with 
regard to the primary outcome were consistent 
across prespecified baseline subgroups (Fig. S3).
Post hoc landmark analyses set at 30 days for 
the primary outcome and the principal secondary 








Age — yr 74.0±9.5 74.1±9.8
Female sex — no. (%) 326 (32.5) 340 (34.2)
Body-mass index† 27.2±5.0 27.3±5.0
Diabetes — no. (%) 388 (38.7) 382 (38.5)
Insulin treatment — no. (%) 119 (11.9) 117 (11.8)
Hypertension — no. (%) 796 (79.4) 807 (81.3)
Hyperlipidemia — no. (%) 643 (64.1) 619 (62.3)
Current smoker — no./total no. (%) 93/993 (9.4) 108/987 (10.9)
Previous myocardial infarction — no. (%) 264 (26.3) 249 (25.1)
Previous PCI — no. (%) 237 (23.6) 230 (23.2)
Previous coronary-artery bypass grafting — no. (%) 77 (7.7) 66 (6.6)
Previous stroke or transient ischemic attack — no. (%) 135 (13.5) 124 (12.5)
Peripheral vascular disease — no. (%) 106 (10.6) 95 (9.6)
Atrial fibrillation — no. (%) 328 (32.7) 316 (31.8)
Left ventricular ejection fraction ≤35% — no./total no. (%) 82/711 (11.5) 77/703 (11.0)
Silent ischemia — no./total no. (%) 88/967 (9.1) 103/935 (11.0)
Chronic coronary syndrome — no./total no. (%) 368/967 (38.1) 361/935 (38.6)
Acute coronary syndrome — no./total no. (%) 511/967 (52.8) 471/935 (50.4)
Unstable angina — no./total no. (%) 189/967 (19.5) 171/935 (18.3)
NSTEMI — no./total no. (%) 262/967 (27.1) 252/935 (27.0)
STEMI — no./total no. (%) 60/967 (6.2) 48/935 (5.1)
*  Plus–minus values are means ±SD. NSTEMI denotes non–ST-segment elevation myocardial infarction, PCI percutane-
ous coronary intervention, and STEMI ST-segment elevation myocardial infarction.
†  The body-mass index is the weight in kilograms divided by the square of the height in meters.
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outcome are shown in Table S16. Time-to-event 
curves with landmark analysis that were analyzed 
according to the Kaplan–Meier method are shown 
in Figures S4 through S7. Between 0 and 30 days, 
the primary outcome occurred in 10.7% of the 
patients in the zotarolimus-eluting stent group 
and in 9.6% of those in the polymer-free drug-
coated stent group. Between 31 days and 1 year, 
the comparable percentages were 6.9% and 8.2%, 
respectively.
Discussion
Among patients at high bleeding risk who were 
treated with 1 month of dual antiplatelet therapy 
after PCI, polymer-based zotarolimus-eluting 
stents were found to be noninferior to polymer-
free drug-coated stents at 1 year with regard to 
both safety (as shown by the composite outcome 
of death from cardiac causes, myocardial infarc-
tion, or stent thrombosis) and effectiveness (as 
shown by the composite outcome of death from 
cardiac causes, target-vessel myocardial infarction, 
or clinically indicated target-lesion revascular-
ization).
This trial adds to the body of evidence from 
previous trials involving patients at high bleeding 
risk.6,7,9 Features of high bleeding risk are frequent 
in patients undergoing PCI, and in the past, these 
patients often received bare-metal stents.2-4 Cur-
rent guidelines recommend 3 to 6 months of 
dual antiplatelet therapy in patients at high 
bleeding risk after the implantation of drug-
eluting stents.1,15-17 The ZEUS (Zotarolimus-Eluting 
Endeavor Sprint Stent in Uncertain DES [Drug-
Eluting Stent] Candidates) and SENIOR (Short 
Duration of Dual Antiplatelet Therapy with Syn-
ergy II Stent in Patients Older Than 75 Years 
Undergoing Percutaneous Coronary Revascular-
ization) trials showed that such patients receiving 
the Endeavor zotarolimus-eluting stent7 or the 
bioresorbable polymer-based everolimus-eluting 
stent6 with abbreviated dual antiplatelet therapy 
(1 to 6 months) had better outcomes than pa-
tients receiving bare-metal stents. The LEADERS 
FREE trial showed that polymer-free umirolimus-
coated stents were superior to bare-metal stents 
in terms of both safety and effectiveness in pa-
tients at high bleeding risk who were treated with 
1 month of dual antiplatelet therapy.9
The present trial compared a contemporary, 
durable, polymer-based, slow-release, zotarolimus-
eluting stent with the same polymer-free drug-
coated stent that was used in the LEADERS FREE 
trial in patients at high bleeding risk who were 
treated with 1 month of dual antiplatelet therapy. 
The proportion and distribution of features of 
high bleeding risk were similar in the LEADERS 
FREE trial and the present trial. More than 90% 
of patients in the two trial groups in the present 
trial discontinued dual antiplatelet therapy after 
1 month, as required by the protocol. Stent throm-
bosis and other ischemic events after 30 days were 
infrequent, and the incidence of these events was 
similar in the two groups. The present findings 
show that polymer-based zotarolimus-eluting 
stents may be safely and effectively used in pa-










Age ≥75 yr 613 (61.1) 618 (62.3)
Oral anticoagulation therapy planned 
to continue after PCI
386 (38.5) 383 (38.6)
Hemoglobin <11 g/dl or transfusion 
within 4 wk before procedure
156 (15.6) 155 (15.6)
Creatinine clearance <40 ml/min 143 (14.3) 154 (15.5)
Non-skin cancer diagnosed or treated 
within previous 3 yr
85 (8.5) 71 (7.2)
Surgery planned in next 12 mo 56 (5.6) 81 (8.2)
Expected nonadherence to prolonged 
dual antiplatelet therapy
39 (3.9) 47 (4.7)
Stroke in previous 12 mo 29 (2.9) 32 (3.2)
Hospital admission for major bleeding 
in previous 12 mo
30 (3.0) 18 (1.8)
NSAID or glucocorticoid use for  
≥30 days after PCI
24 (2.4) 23 (2.3)
Previous intracerebral hemorrhage 20 (2.0) 18 (1.8)
Thrombocytopenia† 15 (1.5) 19 (1.9)
Severe chronic liver disease‡ 8 (0.8) 12 (1.2)
*  Data for one patient in the polymer-free drug-coated stent group were not 
included in this analysis because the patient underwent randomization before 
it was determined that no inclusion criteria were met. NSAID denotes nonste-
roidal antiinflammatory drug.
†  Thrombocytopenia was defined as a platelet count of less than 100,000 per 
cubic millimeter.
‡  Severe chronic liver disease was defined as variceal hemorrhage, ascites, he-
patic encephalopathy, or jaundice.
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tients at high bleeding risk who are treated with 
a duration of dual antiplatelet therapy as short as 
1 month. This is noteworthy because more than 
50% of the patients in our trial presented with 
acute coronary syndromes. The trial thus extends 
earlier results suggesting that bleeding, more than 
ischemic risk, should determine clinical decision 
making regarding the duration of dual antiplatelet 
therapy.18
Similar to the results in the LEADERS FREE 
trial (but at variance with results in other tri-
als,6,7 which used more conservative definitions 
of myocardial infarction19), the outcomes in this 
trial were adjudicated according to the Third 
Universal Definition of Myocardial Infarction.14 
Event rates for the primary outcome were higher 
in this trial than in the LEADERS FREE trial, 
which was driven by a greater incidence of peri-
procedural myocardial infarction in both groups. 
These higher rates may be due to differences in 
patient populations but are more likely to be due 
to differences in ascertainment and adjudication 
of events between the trials. The vast majority of 
diagnoses of periprocedural myocardial infarc-
tions in the present trial were based on angio-
graphic findings, without symptoms or electro-
cardiographic changes, in patients in whom both 
preprocedural and postprocedural troponin levels 
were measured (Table S15). Conversely, the rates 
of death, death from cardiac causes, and stent 










P Value for 
Noninferiority
number (percent) percentage points
Primary outcome: death from cardiac 
causes, myocardial infarc-
tion, or stent thrombosis†
169 (17.1) 164 (16.9) 0.2 (−3.1 to 3.5) 0.01
Principal secondary outcome: target- 
lesion failure‡
174 (17.6) 169 (17.4) 0.2 (−3.2 to 3.5) 0.007
Target-vessel failure§ 177 (17.9) 175 (18.1) −0.1 (−3.5 to 3.3)
Death
Any death 87 (8.8) 72 (7.4) 1.4 (−1.0 to 3.8)
Death from cardiac causes 44 (4.5) 36 (3.7) 0.7 (−1.0 to 2.5)
Target-vessel myocardial infarction¶ 126 (12.8) 136 (14.0) −1.3 (−4.3 to 1.7)
Myocardial infarction¶
Any myocardial infarction 132 (13.4) 142 (14.7) −1.3 (−4.4 to 1.8)
Periprocedural 93 (9.4) 77 (7.9) 1.5 (−1.0 to 4.0)
Spontaneous 45 (4.6) 69 (7.1) −2.6 (−4.6 to -0.5)
Q-wave 12 (1.2) 12 (1.2) 0.0 (−1.0 to 1.0)
Non–Q-wave 120 (12.1) 132 (13.6) −1.5 (−4.4 to 1.5)
Stent thrombosis‖
Definite or probable 13 (1.3) 20 (2.1) −0.7 (−1.9 to 0.4)
Early (≤30 days) 6 (0.6) 13 (1.3) −0.7 (−1.6 to 0.1)
Late (31–365 days) 7 (0.7) 7 (0.7) 0.0 (−0.8 to 0.7)
Definite 9 (0.9) 12 (1.2) −0.3 (−1.2 to 0.6)
Probable 4 (0.4) 8 (0.8) −0.4 (−1.1 to 0.3)
Stroke** 22 (2.2) 22 (2.3) 0.0 (−1.4 to 1.3)
Major adverse cardiac event†† 215 (21.8) 204 (21.1) 0.7 (−2.9 to 4.3)
Revascularization
Clinically indicated target-lesion  
revascularization
28 (2.8) 39 (4.0) −1.2 (−2.8 to 0.4)
Clinically indicated target-vessel  
revascularization
36 (3.6) 51 (5.3) −1.6 (−3.4 to 0.2)
Any revascularization 57 (5.8) 66 (6.8) −1.0 (−3.2 to 1.1)
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thrombosis were similar to those in the LEADERS 
FREE trial. Bleeding was relatively frequent, but 
the incidence was balanced in the two trial 
groups.
These findings should be interpreted in view 
of several limitations. First, this trial was single-
blind because it was not possible for operators 
to be unaware of the device type. Indeed, we ob-
served more frequent crossover in patients who 
had been assigned to receive polymer-free drug-
coated stents than in those assigned to receive 
polymer-based zotarolimus-eluting stents, which 
may have contributed to the observed differences 
in device success. However, patients and outcome 
assessors were unaware of the treatment assign-
ments. Second, the trial was powered for nonin-
feriority testing for the primary outcome and the 
principal secondary outcome but not for superi-
ority testing. The trial was also not powered to 
examine differences in lower-frequency second-
ary outcomes such as stent thrombosis and target-
lesion revascularization, and these analyses were 
not adjusted for multiple comparisons. Finally, 
neither the present trial nor the LEADERS FREE 
trial had a control group of patients taking dual 
antiplatelet therapy for 3 or 6 months. Therefore, 
it is unknown whether patients at high bleeding 
risk who were selected to undergo PCI would 
have a superior net clinical benefit with a 
course of dual antiplatelet therapy longer than 
1 month.
In conclusion, among patients at high bleed-
ing risk, a strategy of PCI with a polymer-based 










P Value for 
Noninferiority
number (percent) percentage points
Bleeding event, according to BARC 
type‡‡
BARC type 1–5 175 (17.7) 158 (16.3) 1.4 (−1.9 to 4.7)
BARC type 2–5 149 (15.1) 133 (13.7) 1.4 (−1.8 to 4.5)
BARC type 3–5 48 (4.9) 43 (4.4) 0.4 (−1.4 to 2.3)
*  The modified intention-to-treat population included all patients in the trial who had known values (i.e., patients who 
had not withdrawn or were lost to follow-up). Percentages indicate patients who had an event up to 365 days after 
the index procedure. Risk differences may not calculate as expected owing to rounding. The 95% confidence intervals 
have not been adjusted for multiple comparisons, and therefore inferences drawn from these intervals may not be 
reproducible.
†  The upper boundary of the one-sided 95% confidence interval was 3.0 percentage points, the upper boundary of the 
one-sided 97.5% confidence interval was 3.5 percentage points, and the noninferiority margin was 4.1 percentage 
points. The relative risk was 1.01 (upper boundary of the one-sided 95% CI, 1.19; upper boundary of the one-sided 
97.5% CI, 1.23). The P value for noninferiority is one-sided and was calculated by the Farrington–Manning test.
‡  The principal secondary outcome of target-lesion failure was a composite of death from cardiac causes, target-vessel 
myocardial infarction (Q-wave and non–Q-wave), or clinically indicated target-lesion percutaneous or surgical re-
vascularization. The upper boundary of the one-sided 95% confidence interval was 3.0 percentage points, the upper 
boundary of the one-sided 97.5% confidence interval was 3.5 percentage points, and the noninferiority margin was 
4.4 percentage points. The relative risk was 1.01 (upper boundary of the one-sided 95% CI, 1.19; upper boundary 
of the one-sided 97.5% CI, 1.22). The P value for noninferiority is one-sided and was calculated by the Farrington–
Manning test.
§  Target-vessel failure was defined as a composite of death from cardiac causes, target-vessel myocardial infarction, or 
clinically driven target-vessel revascularization by percutaneous or surgical methods.
¶  Myocardial infarction was assessed according to the Third Universal Definition of Myocardial Infarction.14
‖  Stent thrombosis was defined according to the Academic Research Consortium (see the End Point Definitions sec-
tion in the Supplementary Appendix).
**  The definition of stroke is provided in the End Point Definitions section in the Supplementary Appendix.
††  A major adverse cardiac event was defined as death from any cause, myocardial infarction, or clinically driven target-
lesion revascularization.
‡‡  Bleeding was defined according to Bleeding Academic Research Consortium (BARC) criteria (see the End Point 
Definitions section in the Supplementary Appendix). BARC types range from 0 to 5, with higher values indicating 
greater severity of bleeding.
Table 3. (Continued)
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of dual antiplatelet therapy was noninferior to a 
polymer-free drug-coated stent with regard to a 
composite outcome of death from cardiac causes, 
myocardial infarction, or stent thrombosis, as 
well as with regard to target-lesion failure.
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Figure 2. Kaplan–Meier Time-to-Event Curves for the Principal Secondary Outcome of Target-Lesion Failure.
Target-lesion failure was defined as a composite of death from cardiac causes, target-vessel myocardial infarction, 
or clinically indicated target-lesion revascularization. Data for patients who were lost to follow-up or withdrew from 
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